Pluri 授予 ZEO 再生醫學產品組合的美國獨家授權

Pluri 簽訂合作協議，授予 ZEO 在美國製造和商業化其再生醫學產品的獨家授權（美容/護膚/化妝品/獸醫用途的有限權利）。作為交換，Pluri 獲得 ZEO 50% 的股權以及額外股權的認股權證、董事會提名權和權利金。

關鍵事實

申報時間: 2026年10月30日下午12:30
事件: 合作 / 授權交易
方向: 中性
公司: PLURPluri Inc.
資產: regenerative medicine product portfolio
來源: SEC 8-K
可信度: 有出處
股權持股: 50%
額外認股權證: 7.5%

來源摘錄

false 0001158780 0001158780 2026-10-21 2026-10-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 30, 2026 ( October 21, 2026 ) PLURI INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-31392 98-0351734 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) MATAM Advanced Technology Park Building No. 5 Haifa , Israel 3508409 (Address of Principal Executive Offices) (Zip Code) 011 972 74 710 7171 (Registrant’s telephone number, including area code) (Former name or form

SEC 8-K